- Garboczi DN, Ghosh P, Utz U, et al. Structure of the complex between human T cell receptor, viral peptide, and HLA-A2. Nature 1996; 384: 134-41.
- Rammensee HG; Friede T, Stevanovic S. MHC ligands and peptide motifs: first listing. Immunogenetics 1995; 41: 178-228.
- Kropshofer H, Hammerling GJ, Vogt A. How HLA-DM edits the MHC class II peptide repertoire: survival of the fittest? Immunol Today 1997; 18: 77-82.
- Bodmer JG, Marsh SGE, Albert ED, et al. Nomenclature for factors of the HLA system, 1996. Hum Immunol 1997; 53: 98-128.
- Elliott T. How does TAP associate with MHC class I molecules? Immunol Today 1997; 18: 375-9.
- Maffei A, Papadopoulos K, Harris PE. MHC class I antigen processing pathways. Hum Immunol 1997; 54: 91-103.
- Koopman JO, Hammerling GJ, Momburg F. Generation, intracellular transport and loading of peptides associated with MHC class I molecules. Curr Opin Immunol 1997; 9: 80-8.
- Pieters J. MHC class II restricted antigen presentation. Curr Opin Immunol 1997; 9: 89-96.
- Amiel JL. Study of the Leukocyte Phenotypes in Hodgkin's Disease. Histocompatibility Testing. Copenhagen: Munksgaard, 1967.
- Brewerton DA, Caffrey M, Hart FD, et al. Ankylosing spondylitis and HL-A27. Lancet 1973; i: 904-7.
- Schlosstein L, Terasaki PT, Bluestone R, Pearson GM. High association of HL-A antigen, W27, with ankylosing spondylitis. New Engl J Med 1973; 288: 704-5.
- Tiwari JL, Terasaki PI. HLA and Disease Associations. New York: Springer Verlag, 1985.
- Davies JL, Kawaguchi Y, Bennett ST, et al. A genome wide search for human type 1 diabetes susceptibility genes. Nature 1994; 371: 130-7.
- Brown MA, Pile KD, Kennedy LG, et al. A genome-wide screen for susceptibility loci in ankylosing spondylitis. Arthritis Rheum 1998; 41: 588-95.
- Greenberg A. Linkage analysis of "necessary" disease loci versus "susceptibility" loci. Am J Hum Genet 1993; 52: 135-43.
- Rubin LA, Amos CI, Wade JA, et al. Investigating the genetic basis for ankylosing spondylitis: linkage studies with the major histocompatibility complex region. Arthritis Rheum 1994; 37: 1212-20.
- Isomaki H, Koota K, Martio J, et al. HL-A27 and arthritis. Ann Clin Res 1975; 7: 138-45.
- Honen J, Hakala M, Reijonen H, Tilikainen A. B27 bearing HLA haplotypes in rheumatoid arthritis: characterization in Finnish patients. Hum Immunol 1991; 30: 7-10.
- Gonzalez-Roces S, Alvarez MV, Gonzalez S, et al. HLA-B27 polymorphism and worldwide susceptibility to ankylosing spondylitis. Tissue Antigens 1997; 49: 116-23.
- Lopez de Castro JA. The pathogenetic role of HLA-B27 in chronic arthritis. Curr Opin Immunol 1998; 10: 59-66.
- D'Amato M, Fiorillo MT, Carcassi C, et al. Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. Eur J Immunol 1995; 25: 3199-201.
- Lopez-Larrea C, Sujirachato K, Mehra NK, et al. HLA-B27 subtypes in Asian patients with ankylosing spondylitis: evidence for new associations. Tissue Antigens 1995; 45: 169-76.
- Nasution AR, Mardjuadi A, Kunmartini S, et al. HLA-B27 subtypes positively and negatively associated with spondyloarthropathy. J Rheumatol 1997; 24: 1111-4.
- Hill AV, Allsopp CE, Kwiatkowski D, et al. HLA-class I typing by PCR: HLA-B27 and an African subtype. Lancet 1991; 337: 640-2.
- Brown M, Jepson A, Young A, et al. Spondyloarthritis in West Africa: evidence for a non-B27 protective effect. Ann Rheum Dis 1997; 56: 68-70.
- Khan M, Braun JW, Jushner J, et al. HLA-B27 in ankylosing spondylitis: differences in frequency and relative risks in American blacks and Caucasians. J Rheumatol 1997; 4 (Suppl 3): 39-43.
- MacLean L. HLA-B27 subtypes: implications for the spondyloarthropathies. Ann Rheum Dis 1992; 51: 929-31.
- Benjamin R, Parham P. Guilt by association: HLA-B27 and ankylosing spondylitis. Immunol Today 1990; 11: 137-42.
- Robinson WP, van der Linden SM, Khan MA, et al. HLA-Bw60 increases susceptibility to ankylosing spondylitis in HLA-B27+ patients. Arthritis Rheum 1989; 32: 1135-41.
- Brown MA, Pile KD, Kennedy LG, et al. HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. Ann Rheum Dis 1996; 55: 268-70.
- Wordsworth BP, Pile KD, Buckley JD, et al. HLA heterozygosity contributes to susceptibility to rheumatoid arthritis. Am J Hum Genet 1992; 51: 585-91.
- Dausset J. Iso-leuco-anticorps. Acta Haematol 1958; 20: 156-66.
- Doherty PC, Zinkernagel RM. A biological role for the major histocompatibility antigens. Lancet 1975; i: 1406-9.
- Bjorkman PJ, Saper MA, Samraoui B, et al. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987; 329: 506-12.
- Thorsby E. HLA-associated disease susceptibility. Which genes are primarily involved? Immunologist 1995; 3: 51.
- Pile KD. Genetic factors in rheumatoid arthritis: HLA and candidate non-HLA loci. MD Thesis, University of Otago 1994.
- Hall FC, Weeks DE, Camilleri JP, et al. Influence of the HLA-DRB1 locus on susceptibility and severity in rheumatoid arthritis. Q J Med 1996; 89: 821-9.
- Cough A, Faint J, Salmon M, et al. Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Arthritis Rheum 1994; 37: 1166-70.
- O'Dell JR, Nepom BS, Haire C, et al. HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments. Ann Rheum Dis 1998; 57: 209-13.
- Dupont B, Oberfield SE, Smithwick EM, et al. Close genetic linkage between HLA and congenital adrenal hyperplasia (21-hydroxylase deficiency). Lancet 1977; 2: 1309-12.
- Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399-408.
- Pietrangelo A, Camaschella C. Molecular genetics and control of iron metabolism in hemochromatosis. Haematologica 1998; 83: 456-61.
- Powell LW, Bassett ML. Haemochromatosis: diagnosis and management after cloning of the HFE gene. Aust NZ J Med 1998; 28: 159-63.
- Burney R, Pile K, Gibson K, et al. Analysis of the MHC class II encoded components of the HLA class I antigen processing pathway in ankylosing spondylitis. Ann Rheum Dis 1994; 53: 58-60.
- Wordsworth BP, Pile KD, Gibson K, et al. Analysis of the MHC encoded transporters TAP1 and TAP2 in rheumatoid arthritis: linkage with DR4 accounts for the association with a minor TAP2 allele. Tissue Antigens 1993; 42: 53-5.
- Maksymowych WP, Tao S, Li Y, et al. Allelic variation at the TAP1 locus influences disease phenotype in HLA-B27 positive individuals with ankylosing spondylitis. Tissue Antigens 1995; 45: 328-32.
- Maksymowych WP, Wessler A, Schmitt EM, et al. Polymorphism in an HLA linked proteasome gene influences phenotypic expression of disease in HLA-B27 positive individuals. J Rheumatol 1994; 21: 665-9.
- Soizic D, Caillat-Zucman S, Hammer J, et al. Absence of functional relevance of human transporter associated with antigen processing polymorphism for peptide selection. J Immunol 1997; 159: 2350-7.
- Brown M, Wordsworth P. Predisposing factors to spondyloarthropathies. Curr Opin Rheumatol 1997; 9: 308-14.
- Simmons WA, Leong LY, Satumtira N, et al. Rat MHC-linked peptide transporter alteles strongly influence peptide binding by HLA-B27 but not B27-associated inflammatory disease. J Immunol 1996; 156: 1661-7.
- Khare SD, Luthra HS, David CS. Spontaneous inflammatory arthritis in HLA-B27 transgenic mice lacking beta-2-microglobulin: a model of human spondyloarthropathies. J Exp Med 1995; 182: 1153-8.
- Baum H, Davies H, Peakman M. Molecular mimicry in the MHC: hidden clues to autoimmunity. Immunol Today 1997; 17: 64-70.
- Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995; 80: 695-705.
- Scofield RH, Kurien B, Gross T, et al. HLA-B27 binding of peptide from its own sequence and similar peptides from bacteria: implications for spondyloarthropathies. Lancet 1995; 345: 1542-4.
- Garcia F, Marina A, Lopez de Castro JA. Lack of carboxy-terminal tyrosine distinguishes the B*2706 bound peptide repertoire from those of B*2704 and other HLA-B27 subtypes associated to ankylosing spondylitis. Tissue Antigens 1997; 49: 215-21.
- Tanigaki N, Fruci D, Vigneti E, et al. The peptide binding specificity of HLA-B27 subtypes. Immunogenetics 1994; 40: 192-8.
- Madden DR, Gorga JC, Strominger JL, Wiley DC. The three dimensional structure of HLA-B27 at 2.1A resolution suggests a general mechanism for tight peptide binding to MHC. Cell 1992; 70: 1035-48.
- Barber DF, Obeso O, Carcia-Hoyo R, et al. T-cell receptor usage in alloreactivity against HLA-B*2703 reveals significant conservation of the antigenic structure of B*2705. Tissue Antigens 1996; 47: 478-84.
- Fiorillo MT, Meadows L, D'Amato M, et al. Susceptibility to ankylosing spondylitis correlates with the C terminal residue of peptides presented by various HLA-B27 subtypes. Eur J Immunol 1997; 27: 368-73.
- Hammer RE, Maika SD, Richardson JA, et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human ß2m: an animal model of HLA B27 associated with human disorders. Cell 1990; 63: 1099-12.
- Rath HC, Herfarth HH, Ikeda JS, et al. Normal luminal bacteria, especially bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA B27/human beta 2 microglobulin transgenic rats. J Clin Invest 1996; 98: 945-53.
- Taurog JD, Richardson JA, Croft JT, et al. The germ free state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180: 2359-64.
- Thorsby E. Invited Anniversary Review: HLA associated diseases. Hum Immunol 1997; 53: 1-11.
- Chicz RM, Urban RG, Gorga JC, et al. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993; 178: 27-47.
- Breban M, Fernandez-Sueiro JL, Richardson JA, et al. T cells but not thymic exposure to HLA-B27 are required for the inflammatory disease of HLA-B27 transgenic rats. J Immunol 1996; 156: 794-803.
- Parham P. Presentation of HLA class I derived peptides: potential involvement in allorecognition and HLA-B27 associated arthritis. Immunol Rev 1996; 154: 137-54.
- Khare SD, Bull MJ, Hanson J, et al. Spontaneous inflammatory disease in HLA-B27 transgenic mice is independent of MHC class II molecules: a direct role of B27 heavy chains and not B27 derived peptides. J Immunol 1998; 160: 101-6.
- Marker-Hermann E, Meyer zum Buschenfelde KH, Wildner G. HLA-B27 derived peptides as autoantigens for T lymphocytes in ankylosing spondylitis. Arthritis Rheum 1997; 40: 2047-54.
- Gao XM, Wordsworth P, McMichael AJ, et al. Homocysteine modification of HLA antigens and its immunological consequences. Eur J Immunol 1996; 26: 1443-50.
- McLean L, Hammer RE, Taurog JD. Cytokine profiles and site directed B27 mutation in the HLA-B27 transgenic rat. Hum Immunol 1996; 47: 74.
- Wilcken DEL. Homocysteine and vascular disease. Med J Aust 1998; 168: 431-2.
- Wuorela M, Jalkanen S, Kirveskari J, et al. Yersinia enterocolitica serotype 0:3 a hers the expression of serologic HLA-B27 epitopes on human monocytes. Infect Immun 1997; 65: 2060-6.
- Kapasi K, Inman RD. HLA-B27 expression modulates Gram negative bacterial invasion into transfected L cells. J Immunol 1992; 148: 3554-9.
- Laitio P, Virtala M, Salmi M, et al. HLA-B27 modulates intracellular survival of Salmonella enteritidis in human monocyte cells. Eur J Immunol 1997; 27: 1331-8.
- Warner TF, Madsen J, Starling J, et al. Human HLA-B27 gene enhances susceptibility of rats to oral infection by Listeria monocytogenes. Am J Pathol 1996; 149: 1737-43.
- McGuire W, Hill AVS, Allsop CEM, et al. Variation in the TNF-a promoter region associated with susceptibility to cerebral malaria. Nature 1994; 371: 508-12.
- Verweij CL, Huizinga TWJ. Tumour necrosis factor alpha gene polymorphisms and rheumatic diseases. Br J Rheumatol 1998; 37: 923-6.
- Petrovsky N, Harrison LC. HLA class II associated polymorphism of interferon-? production. Hum Immunol 1997; 53: 12-6.
- Meyer CG, Gallin M, Erttman KD, et al. HLA-D alleles associated with generalized disease, localized disease, and putative immunity in Onchocerca volvulus infection. Proc Natt Acad Sci USA 1994; 91: 7515-9.
- Brown JH, Jordetzky TS, Gorga JC, et al. Three dimensional structure of the human class II histocompatibilhy antigen HLA-DRI. Nature 1993; 364: 33-9.
BROADSHEET NUMBER 51: HLA AND DISEASE ASSOCIATIONS
Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.